Alba A Brandes

Summary

Country: Italy

Publications

  1. pmc AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy A A B, E F Molecular Neuro Oncology Unit, IRCCS Foundation Carlo Besta, Milan, Italy G F, M E Department of Clinical and Experimental Oncology, Medical Oncology, Veneto Institute of Oncology IRCCS Padua, Italy V Z, G L Department of Medical Oncology, IRCCS San Raffaele, Milan, Italy M R Oncology Department, Santa Maria Hospital, Terni, Italy C C Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy A F E O Ospedale Galliera, Genova, Italy M C Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy E M OPIS, Palazzo Aliprandi, Desio MB, Italy M M Roche S p A Medical Affairs and CO, Monza, Italy E P Neuroradiology Department, Bellaria Maggiore Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Ospedale Bellaria, Bologna, Department of Urology
    Neuro Oncol 18:1304-12. 2016
  2. doi request reprint Nitrosoureas in the Management of Malignant Gliomas
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Via Altura 3, 40139, Bologna, Italy
    Curr Neurol Neurosci Rep 16:13. 2016
  3. doi request reprint New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospitals, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy Electronic address
    Crit Rev Oncol Hematol 94:348-59. 2015
  4. pmc Practical management of bevacizumab-related toxicities in glioblastoma
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy
    Oncologist 20:166-75. 2015
  5. doi request reprint Second surgery for recurrent glioblastoma: advantages and pitfalls
    Alba A Brandes
    Department of Medical Oncology, Azienda USL, Bologna, Italy
    Expert Rev Anticancer Ther 13:583-7. 2013
  6. doi request reprint Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma
    A A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospitals, Azienda USL, Bologna, Italy
    Eur J Cancer 48:896-903. 2012
  7. doi request reprint Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET)
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital Bologna, Italy
    Crit Rev Oncol Hematol 71:165-79. 2009
  8. doi request reprint Neuro-oncology: Genetic variation in pediatric and adult brain tumors
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, Italy
    Nat Rev Neurol 6:653-4. 2010
  9. doi request reprint Primary brain tumors in the elderly population
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Via Altura 3, 40139, Bologna, Italy
    Curr Treat Options Neurol 13:427-35. 2011
  10. pmc Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies
    Fabio Girardi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, 40139 Bologna, Italy
    Oncologist 15:683-94. 2010

Detail Information

Publications83

  1. pmc AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy A A B, E F Molecular Neuro Oncology Unit, IRCCS Foundation Carlo Besta, Milan, Italy G F, M E Department of Clinical and Experimental Oncology, Medical Oncology, Veneto Institute of Oncology IRCCS Padua, Italy V Z, G L Department of Medical Oncology, IRCCS San Raffaele, Milan, Italy M R Oncology Department, Santa Maria Hospital, Terni, Italy C C Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy A F E O Ospedale Galliera, Genova, Italy M C Oncology Unit, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy E M OPIS, Palazzo Aliprandi, Desio MB, Italy M M Roche S p A Medical Affairs and CO, Monza, Italy E P Neuroradiology Department, Bellaria Maggiore Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Ospedale Bellaria, Bologna, Department of Urology
    Neuro Oncol 18:1304-12. 2016
    ..We conducted a noncomparative phase II trial (AVAREG) to examine the efficacy of bevacizumab or fotemustine in this setting...
  2. doi request reprint Nitrosoureas in the Management of Malignant Gliomas
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Via Altura 3, 40139, Bologna, Italy
    Curr Neurol Neurosci Rep 16:13. 2016
    ..This review focuses on the role of the nitrosoureas currently used in clinical practice for the treatment of malignant gliomas. ..
  3. doi request reprint New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospitals, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy Electronic address
    Crit Rev Oncol Hematol 94:348-59. 2015
    ..The present review focuses on the state of the art for adult medulloblastoma treatment and on novel molecular advances and their future implications in the treatment of this disease. ..
  4. pmc Practical management of bevacizumab-related toxicities in glioblastoma
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy
    Oncologist 20:166-75. 2015
    ..Finally, we identified risk factors and proposed preventive and therapeutic measures for these adverse events. ..
  5. doi request reprint Second surgery for recurrent glioblastoma: advantages and pitfalls
    Alba A Brandes
    Department of Medical Oncology, Azienda USL, Bologna, Italy
    Expert Rev Anticancer Ther 13:583-7. 2013
    ....
  6. doi request reprint Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma
    A A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospitals, Azienda USL, Bologna, Italy
    Eur J Cancer 48:896-903. 2012
    ....
  7. doi request reprint Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET)
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital Bologna, Italy
    Crit Rev Oncol Hematol 71:165-79. 2009
    ..An important challenge for the future will be the biological characterization of medulloblastoma, with the identification of specific genetic patterns of patients with a better or a worse prognosis...
  8. doi request reprint Neuro-oncology: Genetic variation in pediatric and adult brain tumors
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, Italy
    Nat Rev Neurol 6:653-4. 2010
    ..Age-dependent gene expression might affect tumor biology; therefore, therapies for adult medulloblastomas or gliomas might not produce the same clinical outcomes in pediatric patients, and vice versa...
  9. doi request reprint Primary brain tumors in the elderly population
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Via Altura 3, 40139, Bologna, Italy
    Curr Treat Options Neurol 13:427-35. 2011
    ..However, the schedule to follow and the best dosage have yet to be satisfactorily established...
  10. pmc Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies
    Fabio Girardi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, 40139 Bologna, Italy
    Oncologist 15:683-94. 2010
    ..In the present paper, the most frequent cardiovascular toxicities and their underlying mechanisms are investigated, with a view to providing indications for effective patient management...
  11. pmc O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital, Bologna, Italy
    Neuro Oncol 12:283-8. 2010
    ..MGMT methylation status determined at first surgery appears to be of prognostic value; however, it is not predictive of outcome following second surgery...
  12. doi request reprint Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
    Expert Rev Anticancer Ther 10:179-84. 2010
    ..New-generation tyrosine kinase inhibitors, which have a broader target, are now considered the key to treatment for breast cancer...
  13. doi request reprint EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma
    Alba A Brandes
    Bellaria and Maggiore Hospitals, Bologna, Department of Medical Oncology, Italy
    Eur J Cancer 46:348-54. 2010
    ....
  14. doi request reprint Glioblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda ASL, Bologna, Italy
    Crit Rev Oncol Hematol 67:139-52. 2008
    ..At time of recurrence/progression, a nitrosourea-based chemotherapy constitutes a reasonable option, as well as a temozolomide re-challenge for patients without progression during prior temozolomide treatment...
  15. pmc Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, AUSL Bologna, Bologna, Italy
    Neuro Oncol 10:361-7. 2008
    ..The potential pitfalls in clinical studies attempting to make a differential diagnosis between radionecrosis and disease progression are also discussed...
  16. doi request reprint MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda Unità Sanitaria Locale of Bologna, Bologna, Italy
    J Clin Oncol 26:2192-7. 2008
    ..The radiologic images obtained in this setting can be difficult to interpret since they may show radiation-induced pseudoprogression (psPD) rather than disease progression...
  17. doi request reprint Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 115:3512-8. 2009
    ....
  18. doi request reprint Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status
    Alba A Brandes
    Department of Medical Oncology, Azienda USL Bellaria Maggiore Hospital, Bologna, Italy
    J Clin Oncol 27:1275-9. 2009
    ....
  19. pmc Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, Ospedale Bellaria Maggiore, Bologna, Italy
    Cancer Chemother Pharmacol 64:769-75. 2009
    ..Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide...
  20. ncbi request reprint The treatment of adults with medulloblastoma: a prospective study
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Int J Radiat Oncol Biol Phys 57:755-61. 2003
    ..To assess in a prospective trial the value of prognostic factors and the outcome of medulloblastoma in adults...
  21. ncbi request reprint Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Alba A Brandes
    Department of Medical Oncology, University Hospital of Padova, Padova, Italy
    J Clin Oncol 22:4779-86. 2004
    ..The aim of the present multicenter phase II trial, therefore, was to ascertain the efficacy of second-line carmustine (BCNU) and irinotecan chemotherapy...
  22. pmc Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
    Alba A Brandes
    Department of Medical Oncology, Istituto Oncologico Veneto IRCCS Padova, Padova, Italy
    Neuro Oncol 8:253-60. 2006
    ..Even if no survival advantage has been demonstrated for temozolomide versus PCV, we conclude that temozolomide should be preferred because of its greater tolerability...
  23. doi request reprint Patient outcomes following second surgery for recurrent glioblastoma
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy
    Future Oncol 12:1039-44. 2016
    ..The most appropriate management of recurrent glioblastoma is still controversial. In particular, the role of surgery at recurrence remains uncertain...
  24. ncbi request reprint Long-term results of a prospective study on the treatment of medulloblastoma in adults
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale USL Bellaria Maggiore Hospital, Bologna, Italy
    Cancer 110:2035-41. 2007
    ..Furthermore, the different therapeutic strategies used in these patients has made it difficult to assess survival rates and prognostic factors...
  25. ncbi request reprint A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Padova, Italy
    Cancer 104:143-8. 2005
    ..No data on the role of chemotherapy in recurrent ependymal tumors are available in adults. The aim of the current study was to investigate outcomes after salvage chemotherapy in this setting...
  26. doi request reprint Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas
    A Tosoni
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, 40139, Bologna, Italy
    J Neurooncol 89:179-85. 2008
    ..Patients with recurrent or progressive low grade gliomas survive for a decade or more following diagnosis, and may be at a higher risk for treatment-related complications, such as cognitive impairment from radiotherapy...
  27. ncbi request reprint Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, Bologna, Italy
    J Clin Oncol 24:4746-53. 2006
    ..The aim of this study was to evaluate correlations between 1p/19q deletions, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation, and response rate to TMZ in this setting...
  28. ncbi request reprint Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Oncology 63:38-41. 2002
    ....
  29. ncbi request reprint A prospective study on glioblastoma in the elderly
    Alba A Brandes
    Department of Medical Oncology, Azienda Ospedale Universita, Padova, Italy
    Cancer 97:657-62. 2003
    ..Elderly patients (age > 65 years) with glioblastoma multiforme frequently are excluded from clinical studies, and prospective trials for patients with this age group do not exist to date...
  30. doi request reprint Treatment options for recurrent glioblastoma: pitfalls and future trends
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Bologna, Italy
    Expert Rev Anticancer Ther 9:613-9. 2009
    ..New therapeutic strategies, such as targeted therapies and anti-angiogenic treatments that appear promising with regard to improving the results at the time of recurrence are discussed...
  31. doi request reprint Post progression survival in glioblastoma: where are we?
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Maggiore Hospitals, Azienda USL IRCCS Institute of Neurological Sciences, Via Altura 3, 40139, Bologna, Italy
    J Neurooncol 121:399-404. 2015
    ..2 % (95 % CI 41.5-54.9 %) and PPS-12: 31.7 % (95 % CI 25.2-38.2 %). PPS in unselected patients treated with alkylating agents is about 8 months. PPS rates could be of interest as an end point in future studies in recurrent GBM...
  32. pmc EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Azienda USL of Bologna, Italy
    Neuro Oncol 14:1503-10. 2012
    ..2-1.4) and 6-month PFS was 7.7%. In this phase I study of recurrent glioblastoma patients, the combination of CCNU and dasatinib showed significant hematological toxicities and led to suboptimal exposure to both agents...
  33. doi request reprint Association between response to primary treatments and MGMT status in glioblastoma
    Enrico Franceschi
    Department of Medical Oncology, Azienda USL Bellaria Maggiore, Bologna, Italy
    Expert Rev Anticancer Ther 8:1781-6. 2008
    ..Therefore, future strategies in the treatment of glioblastoma patients will include stratification for MGMT methylation status, and various approaches based on epigenetic features are currently under investigation...
  34. doi request reprint MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years
    Andres J M Ferreri
    From the Unit of Lymphoid Malignancies A J M F, UTMO and Hematology Unit, Department of Onco Hematology F C, and Medical Oncology Unit, Department of Oncology M R, San Raffaele Scientific Institute, Milan Department of Medical Oncology A A B, Bellaria Maggiore Hospital, Azienda Unita Sanitaria Locale, Bologna Division of Hematology M M, Ospedale di Ancona Department of Medical Oncology and Hematology M B, Istituto Clinico Humanitas, Rozzano Division of Medical Oncology A M S, National Cancer Institute, Aviano Division of Hematology F I, Ospedale di Reggio Emilia Division of Hematology F Z, Ospedale di Udine Division of Hematology C S, Ospedale di Reggio Calabria Division of Hematology F B, Ospedale Maggiore di Novara Division of Hematology G C, Istituto Nazionale dei Tumori Pascale di Napoli and the Division of Hematology L B, Ospedale Maggiore di Milano, Italy
    Neurology 82:1370-3. 2014
    ..We report updated results at a median follow-up of 12 years of a phase II trial assessing first-line MATILDE chemotherapy and response-tailored radiotherapy in patients with primary CNS lymphomas (PCNSL)...
  35. ncbi request reprint Treatment of brain metastases in uncommon tumors
    Alicia Tosoni
    Department of Medical Oncology, Azienda Ospedale, University of Padova, Italy
    Expert Rev Anticancer Ther 4:783-93. 2004
    ..Chemotherapy could be useful in patients with asymptomatic brain metastases and uncontrolled extracranial disease, depending on performance status and previous chemotherapy received...
  36. ncbi request reprint The effect of re-operation on survival in patients with recurrent glioblastoma
    Enrico Franceschi
    Department of Medical Oncology, Azienda USL IRCCS Institute of Neurological Sciences, Bologna, Italy
    Anticancer Res 35:1743-8. 2015
    ..Treatment options for glioblastoma (GBM) at recurrence have limited efficacy. Re-surgery has been used for confirmation of recurrent disease and to provide relief of symptoms but the real impact on survival is unknown...
  37. ncbi request reprint Prognostic factors for anaplastic astrocytomas
    Alessia Compostella
    Department of Medical Oncology, Istituto Oncologico Veneto IRCCS, Padova, Italy
    J Neurooncol 81:295-303. 2007
    ..Our knowledge in this field is still limited, and remains an issue of great concern...
  38. doi request reprint Chemotherapy in breast cancer patients with brain metastases: have new chemotherapic agents changed the clinical outcome?
    Alicia Tosoni
    Department of Medical Oncology, Bellaria Maggiore Hospital, Via Altura 3, Bologna, Italy
    Crit Rev Oncol Hematol 68:212-21. 2008
    ..More recent drugs with a high impact on the clinical outcome of metastatic breast cancer patients, such as taxanes or trastuzumab, play only a limited role in the treatment of brain metastases...
  39. ncbi request reprint Adjuvant chemotherapy in the treatment of high grade gliomas
    Sara Lonardi
    Department of Medical Oncology, Padova University Hospital, Via Gattamelata 64, 35128 Padua, Italy
    Cancer Treat Rev 31:79-89. 2005
    ..Randomized comparisons with nitrosoureas are lacking and represent a major issue to be studied in future phase III trials...
  40. doi request reprint High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
    Andres J M Ferreri
    Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, Milan, Italy
    Lancet 374:1512-20. 2009
    ..We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma...
  41. doi request reprint Treatment of brain metastases from HER-2-positive breast cancer: current status and new concepts
    Marco Bartolotti
    Department of Medical Oncology, Azienda USL, Via Altura 3 40139, Bologna, Italy
    Future Oncol 9:1653-64. 2013
    ..In this review we focus on the available clinical data regarding the treatment of BM from HER-2-positive breast cancer and on new concepts about the treatment and evaluation of the CNS response. ..
  42. doi request reprint End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Maggiore Hospital, Bologna, Italy
    Expert Rev Anticancer Ther 11:1713-7. 2011
    ..Thus, there is a need for solid end points to evaluate the role of these agents in Phase II trials in the field of neuro-oncology...
  43. ncbi request reprint The pathogenesis and treatment of brain metastases: a comprehensive review
    Alicia Tosoni
    Department of Medical Oncology, University Hospital of Padova, Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 52:199-215. 2004
    ..A better understanding of the complex processes underlying the development of brain metastasis will enable us to develop more satisfactory targeted treatments...
  44. doi request reprint Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
    Alba A Brandes
    Department of Medical Oncology, Azienda Unità Sanitaria Locale Bellaria Maggiore Hospital, Bologna, Italy
    Clin Cancer Res 14:957-60. 2008
    ..As with other targeted agents, prospective trials using specific criteria and standardized methods to evaluate tissue biomarkers are required to find predictors of EGFR inhibitors activity in high-grade glioma patients...
  45. doi request reprint Resistance to antiangiogenic therapies
    Marco Bartolotti
    Department of Medical Oncology, Azienda Unita Sanitaria Locale, Bologna, Italy
    Future Oncol 10:1417-25. 2014
    ..Biomarkers for the prediction of response or resistance to antiangiogenic agents are under evaluation. ..
  46. ncbi request reprint Glioblastoma in the elderly: current and future trends
    Alba A Brandes
    Department of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Crit Rev Oncol Hematol 60:256-66. 2006
    ..Temozolomide appears to be the best available chemotherapy in this population of patients...
  47. ncbi request reprint Medulloblastomas: do molecular and biologic markers indicate different prognoses and treatments?
    Alba A Brandes
    Department of Medical Oncology, University Hospital, Padova, Italy
    Expert Rev Anticancer Ther 3:615-20. 2003
    ....
  48. doi request reprint Maintenance therapy in non-small cell lung cancer
    Giovenzio Genestreti
    Department of Medical Oncology, Azienda USL, Bellaria Hospital IRCCS Institute of Neurological Sciences, Bologna, Italy
    Expert Rev Anticancer Ther 15:839-46. 2015
    ....
  49. ncbi request reprint Current clinical management of gastrointestinal stromal tumors
    Alicia Tosoni
    Department of Medical Oncology, Azienda Ospedale, University of Padova, Italy
    Expert Rev Anticancer Ther 4:595-605. 2004
    ..However, the optimal dose and role of imatinib in an adjuvant or neoadjuvant setting have yet to be defined. Therefore, further studies investigating the mechanism of resistance to imatinib in patients with GIST are warranted...
  50. doi request reprint Relapsed Glioblastoma: Treatment Strategies for Initial and Subsequent Recurrences
    Alicia Tosoni
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Via Altura 4, Bologna, Italy
    Curr Treat Options Oncol 17:49. 2016
    ..Available treatments include nitrosoureas, bevacizumab, or carboplatin plus etoposide. However, more effective therapeutic options are needed...
  51. doi request reprint Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study
    Enrico Franceschi
    Department of Medical Oncology, Bellaria Hospital, Azienda USL IRCCS Institute of Neurological Sciences, Via Altura 3, 40139, Bologna, Italy
    J Neurooncol 128:157-62. 2016
    ..In elderly patients RT/TMZ represent a widely used approach but it is effective with methylated MGMT tumors only. ..
  52. doi request reprint New drugs in the treatment of elderly patients with metastatic castration-resistance prostate cancer
    Giovenzio Genestreti
    Department of Medical Oncology, Bellaria Hospital, AUSL Bologna IRCCS Institute of Neurological Sciences, Bologna Italy
    Tumori 102:361-6. 2016
    ..This review focuses on the safety and efficacy results of these new drugs in elderly patients. ..
  53. doi request reprint Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview
    Giovenzio Genestreti
    Department of Medical Oncology, Bellaria Hospital IRCCS Institute of Neurological Sciences, Azienda USL, Via Altura 3, 47841 Bologna, Italy
    Future Oncol 10:2081-96. 2014
    ..This article summarizes the state-of-the-art treatments in this setting...
  54. doi request reprint The role of systemic and targeted therapies in brain metastases
    Enrico Franceschi
    Medical Oncology Department, Bellaria Maggiore Hospital, Azienda USL of Bologna, Via Altura 3, 40139 Bologna, Italy
    Expert Rev Anticancer Ther 14:93-103. 2014
    ..Local treatments, mainly, whole-brain radiotherapy have been the standard of care, whereas chemotherapy has been considered of limited efficacy due to the potential role of blood-brain barrier. ..
  55. ncbi request reprint Non-cytotoxic therapies for malignant gliomas
    Umberto Basso
    Department of Medical Oncology, Azienda Ospedale Università of Padova, Italy
    J Neurooncol 58:57-69. 2002
    ....
  56. doi request reprint Contribution of microRNA analysis to characterisation of pancreatic lesions: a review
    Michela Visani
    Department of Pharmacy and Biotechnology, University of Bologna, Bologna, Italy
    J Clin Pathol 68:859-69. 2015
    ..The aim of this review is to focus on miRNA expression in pancreatic cancer and their putative role in early characterisation of pancreatic lesions. ..
  57. ncbi request reprint Shedding light on adult medulloblastoma: current management and opportunities for advances
    Alba A Brandes
    From the Department of Medical Oncology, Azienda USL IRCCS Institute of Neurological Science, Bologna, Italy
    Am Soc Clin Oncol Educ Book 34:e82-7. 2014
    ....
  58. ncbi request reprint Adjuvant temozolomide: how long and how much?
    Enrico Franceschi
    Expert Rev Anticancer Ther 8:663-5. 2008
  59. ncbi request reprint Temozolomide in glioblastoma multiforme of the elderly
    Alba A Brandes
    Division of Medical Oncology, Azienda Ospedale, Universita di Padova
    Tumori 88:S69-70. 2002
  60. ncbi request reprint Controversies in the therapy of low-grade glioma: when and how to treat
    Alba A Brandes
    Divisione di Oncologia Direzione Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padova, Italy
    Expert Rev Anticancer Ther 2:529-36. 2002
    ..Current concepts and future perspectives in the treatment of low-grade gliomas drawn from recent scientific literature are here summarized and discussed...
  61. ncbi request reprint State-of-the-art treatment of high-grade brain tumors
    Alba A Brandes
    Medical Oncology Department, Azienda Ospedale Universita, Padova, Italy
    Semin Oncol 30:4-9. 2003
    ..Additional randomized, controlled trials are needed to fully define the best option for first-line chemotherapy in both the adjuvant and recurrent settings in patients with high-grade malignant glioma...
  62. ncbi request reprint The treatment of elderly patients with high-grade gliomas
    Alba A Brandes
    Medical Oncology Department, Azienda Ospedale Universita, Padova, Italy
    Semin Oncol 30:58-62. 2003
    ..Results from larger prospective trials will determine the optimal role of chemotherapy, particularly temozolomide, in elderly patients with malignant gliomas...
  63. ncbi request reprint The European Organisation for Research and Treatment of Cancer strategy for new drug development in brain tumors
    Denis Lacombe
    New Drug Development Program, European Organisation for Research and Treatment of Cancer Data Center, Brussels, Belgium
    Semin Oncol 30:77-80. 2003
    ..By sharing their expertise with the EORTC networks, medical oncologists, neuro-oncologists, and radiologists can assist in the clinical development of potentially active agents in patients with brain tumors...
  64. ncbi request reprint First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Alba A Brandes
    Department of Medical Oncology Direzione, Azienda Ospedale Università Ospedale Busonera, Via Gattamelata 64, 35100 Padua, Italy
    J Clin Oncol 22:1598-604. 2004
    ..The primary end point of the present multicenter phase II study was progression-free survival (PFS) at 6 months (PFS-6); secondary end points included response, toxicity, and overall survival...
  65. ncbi request reprint Review of the prognostic factors in medulloblastoma of children and adults
    Alba A Brandes
    Medical Oncology Department, University Hospital, Via Gattamelata 64, 35100 Padova, Italy
    Crit Rev Oncol Hematol 50:121-8. 2004
    ..Great interest has been expressed in new biological and molecular prognostic factors, which, combined with clinical variables, may allow a more satisfactory stratification of patients...
  66. pmc Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
    Eric Raymond
    Service inter hospitalier de cancérologie, Beaujon University Hospital, Clichy
    J Clin Oncol 26:4659-65. 2008
    ..To evaluate the safety and the efficacy of imatinib in recurrent malignant gliomas...
  67. ncbi request reprint Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial
    René Olivier Mirimanoff
    Department of Radiation Oncology, University Hospital Lausanne, Lausanne, Switzerland
    J Clin Oncol 24:2563-9. 2006
    ..We evaluated in this trial whether the recursive partitioning analysis (RPA) retains its overall prognostic value and what the benefit of the combined modality is in each RPA class...
  68. ncbi request reprint Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer p
    Martin J van den Bent
    Departments of Neurology and Pathology, Daniel den Hoed Cancer Center Erasmus University Hospital, Rotterdam, The Netherlands
    J Clin Oncol 24:2715-22. 2006
    ....
  69. ncbi request reprint 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
    Mathilde C M Kouwenhoven
    Department of Neuro Oncology, Daniel den Hoed Oncology Center, P O Box 5201, 3008AE Rotterdam, The Netherlands
    Eur J Cancer 42:2499-503. 2006
    ..We assessed the impact of 1p and 19q loss on the outcome to first line temozolomide (TMZ) chemotherapy and to second line PCV or TMZ in progressive oligodendroglial tumours...
  70. ncbi request reprint New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology
    Alba A Brandes
    Expert Rev Anticancer Ther 6:1129-31. 2006
  71. ncbi request reprint Challenges and progress in the treatment of adult medulloblastomas
    Enrico Franceschi
    Future Oncol 3:115-7. 2007
  72. ncbi request reprint Adjuvant therapy in glioblastomas: false steps and real advances
    Alba A Brandes
    Expert Rev Anticancer Ther 7:607-8. 2007
  73. ncbi request reprint Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
    Roger Stupp
    Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
    N Engl J Med 352:987-96. 2005
    ..In this trial we compared radiotherapy alone with radiotherapy plus temozolomide, given concomitantly with and after radiotherapy, in terms of efficacy and safety...
  74. ncbi request reprint Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
    Thierry Gorlia
    EORTC Data Centre, Brussels, Belgium
    Lancet Oncol 9:29-38. 2008
    ....
  75. ncbi request reprint Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trial
    Martin J B Taphoorn
    Department of Neurology, Medical Center Haaglanden Westeinde Ziekenhuis, The Hague, The Netherlands
    J Clin Oncol 25:5723-30. 2007
    ....
  76. ncbi request reprint Trastuzumab in CNS progressive metastatic breast cancer
    Alicia Tosoni
    Future Oncol 3:367-9. 2007
  77. ncbi request reprint Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study
    Murielle E L Mauer
    European Organisation for Research and Treatment of Cancer Data Center, Quality of Life Unit, Ave Mounier 83 11, Brussels, Belgium 1200
    J Clin Oncol 25:5731-7. 2007
    ..This is one of a few studies that have explored the value of baseline symptoms and health-related quality of life (HRQOL) in predicting survival in patients with brain cancer...
  78. ncbi request reprint Is intra-arterial chemotherapy useful in high-grade gliomas?
    Umberto Basso
    Divisione di Oncologia Medica Direzione, Ospedale Busonera, Via Gattamelata 64, Azienda Ospedale Universita, 35100 Padova, Italy
    Expert Rev Anticancer Ther 2:507-19. 2002
    ....
  79. ncbi request reprint Current management and prognostic factors for adult ependymoma
    Michele Reni
    Department of Radiochemotherapy, San Raffael H Scientific Institute via Olgettina 60, 20132 Milan, Italy
    Expert Rev Anticancer Ther 2:537-45. 2002
    ..Some important therapeutic issues like the irradiation dose and volume are also analyzed. Finally, the main open questions as well as current and expected investigation trends are discussed...
  80. ncbi request reprint Breast cancer risk in symptomatic women spontaneously undergoing clinical breast examination
    Franco Lumachi
    Endocrine Surgery Unit, Department of Surgical and Gastroenterological Sciences, University of Padua, Medical School, 35128 Padova, Italy
    Anticancer Res 23:3565-8. 2003
    ..80-1.80), and no risk in those with breast pain (OR = 0.86, 95% CI 0.54-1.36) and nipple discharge (OR = 0.8, 95% CI 0.37-1.74). In conclusion, a relationship between breast complaints and the onset of BC does not seem to exist...
  81. ncbi request reprint Recommendations for the management of malignant gliomas in the elderly
    Umberto Basso
    Department of Oncology, Ospedale Busonera, Azienda Ospedale Universita, Padova, Italy
    Expert Rev Anticancer Ther 3:643-54. 2003
    ..Peculiar features of malignant gliomas in the elderly and some practical recommendations of management will be presented and discussed in this review...
  82. ncbi request reprint Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer
    Franco Lumachi
    Department of Surgical and Gastroenterological Sciences, University of Padua, School of Medicine, 35128 Padova, Italy
    Anticancer Res 24:3221-4. 2004
    ....
  83. ncbi request reprint Novel therapeutics in adult malignant brain gliomas
    Michele Reni
    Department of Oncology, San Raffaele H Scientific Institute via Olgettina 60, 20132 Milan
    Expert Opin Investig Drugs 14:643-58. 2005
    ....